Mesenchymal stem cell therapy - Translational Biosciences

Drug Profile

Mesenchymal stem cell therapy - Translational Biosciences

Alternative Names: Mesenchymal Trophic Factor; Mesenchymal Trophic Factor - Translational Biosciences; Trophic factors from umbilical cord mesenchymal stem cells; Trophic factors from umbilical cord mesenchymal stem cells - Translational Biosciences

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Translational Biosciences
  • Class Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple sclerosis; Osteoarthritis

Most Recent Events

  • 26 Apr 2017 Translational Biosciences withdraws a phase-I/II clinical trials in Osteoarthritis in Panama due to no enrollment (Intra-arterial) (SC) (NCT02003131)
  • 17 Mar 2016 Mesenchymal stem cell therapy is still in phase I/II trials for Osteoarthritis and Multiple sclerosis in Panama
  • 09 Jan 2014 Phase-I/II clinical trials in Multiple sclerosis in Panama (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top